What is Gracell Biotechnologies Inc. (GRCL) stock price today?

Gracell Biotechnologies Inc. (GRCL) is currently trading at $10.25, up 0.05% today.

What is GRCL P/E ratio?

Gracell Biotechnologies Inc.'s P/E ratio is -1.55. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is GRCL return on equity (ROE)?

Gracell Biotechnologies Inc.'s return on equity (ROE) is -37.93%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Gracell Biotechnologies Inc.'s market cap?

Gracell Biotechnologies Inc. has a market capitalization of $197.97M.

NASDAQ · Biotechnology

Gracell Biotechnologies Inc. (GRCL) Stock

$10.25 +0.05% NASDAQ: GRCL Healthcare

Valuation

Metric	Value
Price	$10.25
Market Cap	$197.97M
P/E Ratio	-1.55
P/B Ratio	0.68
P/S Ratio	0.00
EPS (TTM)	$-44.85
52-Week High	$10.44
52-Week Low	$1.40
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-37.93%
ROA	-36.68%
ROCE	-43.51%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.13
Current Ratio	6.78

Annual Financials (USD)

Metric	2018	2019	2020	2021	2022
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-63.0M	$-147.0M	$-214.0M	$-464.0M	$-625.0M
Net Profit	$-61.0M	$-132.0M	$-197.0M	$-466.0M	$-608.0M
EPS	$-15.35	$-33.35	$-15.05	$-35.40	$-44.85
Op Margin	—	—	—	-126659.3%	—

Balance Sheet (USD)

Metric	2018	2019	2020	2021	2022
Total Assets	$149.0M	$412.0M	$965.0M	$2.1B	$1.7B
Total Liabilities	$146.0M	$157.0M	$145.0M	$233.0M	$281.0M
Cash	$12.0M	$312.0M	$754.0M	$1.8B	$1.5B
Borrowings	$139.0M	$139.0M	$103.0M	$155.0M	$183.0M

Cash Flow (USD)

Metric	2018	2019	2020	2021	2022
Operating Cash Flow	$-62.0M	$-135.0M	$-198.0M	$-305.0M	$-3.3B
Investing Cash Flow	$-125.0M	$-15.0M	$-173.0M	$-98.0M	$-663.0M
Financing Cash Flow	$139.0M	$350.0M	$756.0M	$1.5B	$228.0M
Net Cash Flow	$-37.0M	$300.0M	$442.0M	$1.1B	$-2.6B
Free Cash Flow	$-73.0M	$-192.0M	$-278.0M	$-361.0M	$-3.6B

Valuation & Return Ratios

Metric	Value
PEG Ratio	-0.08
EV / EBITDA	-0.12
FCF Yield	-271.40%
Quick Ratio	6.78
Interest Coverage	-92.72
Return 1Y	—
Return 3Y	—
Return 5Y	—

About Gracell Biotechnologies Inc.

Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of cell-based therapies, primarily for cancer treatment, within the People's Republic of China. The company's leading investigational therapies include: GC012F: A FasTCAR-enhanced autologous CAR-T product designed to target both BCMA and CD19, currently undergoing Phase I clinical trials for multiple myeloma. GC019F: A FasTCAR-enabled CD19-directed autologous CAR-T therapy, which is progressing through Phase I trials for adult B-cell acute lymphoblastic leukemia (B-ALL) and is also in preclinical development for relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL). GC027: A TruUCAR-powered allogeneic CAR-T product targeting CD7, presently in Phase I clinical development for adult T-cell acute lymphoblastic leukemia. Additionally, Gracell's pipeline features: GC007g: A donor-derived allogeneic CAR-T cell therapy directed at CD19, currently in a Phase 1/2 registrational study for r/r B-ALL. GC502: An off-the-shelf, TruUCAR-enabled allogeneic CAR-T candidate engineered to target both CD19 and CD7, which is in Phase I trials for B-cell malignancies. Beyond these, Gracell maintains a broader portfolio of earlier-stage therapeutic candidates addressing diverse oncological conditions, including ovarian cancer, breast cancer, peripheral T cell lymphoma (a subtype of NHL), and T cell lymphoblastic leukemia. Established in 2017, the company's headquarters are situated in Suzhou, China.

Gracell Biotechnologies Inc. is headquartered in CN.

Gracell Biotechnologies Inc. (GRCL) stock trades at $10.25 with a market capitalization of $197.97M. The stock is valued at a price-to-earnings (P/E) ratio of -1.55, price-to-book of 0.68, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.40 and $10.44, and currently trades 1.8% below its 52-week high.

On profitability, Gracell Biotechnologies Inc. generates a return on equity (ROE) of -37.93%, return on capital employed of -43.51%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.gracellbio.com